Amar Murugan - 01 Mar 2023 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role: SVP, GC & Secretary
Signature: /s/ Jeff Kiekhofer, Attorney-in-Fact for Amar Murugan
Issuer symbol: ATRA
Transactions as of: 01 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 03 Mar 2023, 16:15:34 UTC
Previous filing: 18 Nov 2022
Next filing: 06 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATRA	Common Stock	Award	$0	+155,375	+121%	$0.000000	283,555	01 Mar 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATRA	Employee Stock Option (Right to Buy)	Award	$0	+349,593		$0.000000	349,593	01 Mar 2023	Common Stock	349,593	$3.91	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These restricted stock units vest in 12 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2023, subject to the reporting person's continuous service. "Company Quarterly Vesting Date" means March 1, May 15, August 15 and November 15 of each year.
F2	Includes 594 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2022.
F3	1/36th of the shares subject to the stock option vest and become exercisable each month, with the initial installment vesting on April 1, 2023, subject to the reporting person's continuous service.